**HIV-1 Indian subtype C vaccine constructs for use in humans.**

- This vaccine has been specifically designed for the prevention of HIV-1 subtype C infection in humans particularly in India.

- The vaccine is based on prime-boost strategy in which priming is done with recombinant DNA (rDNA) vaccine construct followed by boosting with recombinant MVA vaccine constructs.

**Milestones achieved:**

- **IP Status:** An Indian patent has been granted & patent no. is 256702 & South African granted & Patent no. SA2006/5498.

- **Validation:** The mandatory preclinical toxicity testing of vaccine constructs is under process.

- **USP of technology:** This is the indigenous technology - HIV vaccine constructs based on recombinant DNA technology to combat HIV-1 subtype C infections, comprising human codon optimized structural genes and non structural genes of Indian strains of HIV-1 subtype C.

- Technology was developed at AIIMS, New Delhi and supported by ICMR.

- ICMR is seeking potential agencies for the up-scaling of technology.